About the Disclosure Reports

“We must give the public information to evaluate whether we are indeed living up to our values.” Deirdre Connelly, GSK President North America Pharmaceuticals


Physician payments:

GlaxoSmithKline works with physicians because they provide valuable knowledge, insight and experience in appropriate disease and therapy areas that are important to the company and the healthcare community. Our goal is to have programs that reflect our values – focus on the best interests of the patient, be transparent about our working relationships, operate with integrity, and respect those with whom we work and serve.

We publish the Physician Payments Report on this website to detail our payments and other transfers of value to those US Health Care Professionals (HCPs) who GSK has engaged as speakers about our medicines and the conditions they are approved to treat. These speaking events are attended by other physicians. We also detail payments to physicians who work with us as advisors to help GSK understand trends in the delivery of healthcare and the evolving needs of patients and providers for more effective medicines and vaccines. Also reported are GSK payments for reasonable expenses incurred by physician speakers and advisers while conducting programs on behalf of GSK such as meals, airfare and lodging. We also report modest meals provided to physicians who attend a speaker program or in-office presentation and other expenses which are non-cash items of value or services such as certain educational items given to a physician.

GSK has set a limit on payments to individual US physicians for speaking, advising, other transfers of value, and other expenses of $100,000 per calendar year.

Speakers – We work with some physicians because they provide valuable knowledge and insight about our medicines and the diseases or conditions our medicines and vaccines are approved to treat. These physicians may lead programs that deliver important information, which can translate to improved patient care. Physicians who lead these educational programs are compensated at fair market value for their time and expertise. We also reimburse physicians for reasonable incidental expenses, such as meals, airfare or lodging, incurred while conducting such programs on behalf of GSK. We also report modest meals provided to physicians who attend a speaker program or in-office presentation where a meal is provided.

In the US, we conduct both a federal and state review to identify and exclude physicians from our speaker programs who have been excluded by the Office of the Inspector General (OIG), have been debarred by the Food and Drug Administration (FDA), or have received a professional sanction and/or disciplinary action from either a federal or state government agency or authority.

Before speaking on behalf of GSK, physicians must complete training to help ensure that they fulfill GSK policies, FDA requirements, as well as responsibilities to peers, colleagues, and patients.

Our speakers must use company-prepared slides to ensure that the information presented is aligned with the FDA approved prescription label for the medicine involved.

We announced in December 2013 ( http://us.gsk.com/html/media-news/pressreleases/2013/gsk-announces-changes-to-its-global-sales-and-marketing-practice.html) that we will stop paying physicians to speak on behalf of our medicines and vaccines. We will increase our focus on alternative approaches that allow us to continue to provide appropriate information about our medicines and vaccines to healthcare professionals. These changes will be in place by the start of 2016.

Advisors – We also work with physicians who share their expertise with our company. Because these advisors possess particular insight and knowledge in their various fields, they can help us to better evaluate scientific issues or data and respond to the emerging needs of patients and other physicians. We compensate these physicians at fair market value for their time and expertise. We also reimburse them for reasonable incidental expenses such as meals, airfare or lodging incurred while advising the company.

More About The Disclosure Reports

Expense and payment data are gathered from across GSK’s financial systems. Transfers of value that occurred between GSK and a US-based physician and related entities are collected. Each transaction is matched to a unique recipient identifier and transactions are aggregated by spend type (consulting, speaker program, business meals, business travel or other value). For some types of expense, GSK processes allow up to 90 days for reconciliation post payment to finalize costs. Transactions not fully reconciled at the time of report publication are  updated for inclusion in a subsequent report.

We are committed to providing as complete and accurate a report as possible. However, despite our best efforts, from time to time errors can occur. As a result, we have established internal processes to continually review and validate our accuracy and disclosures, and to correct those records when errors are identified.

Some medicines are co-promoted by GSK and other companies. For those medicines, this report will not include payments by companies other than GSK.

GSK has set a limit on payments to individual US physicians for speaking, advising, other transfers of value, and other expenses of $100,000 per calendar year.     

Questions about the Physician Payments Report as well as other disclosed reports can be addressed to GSK’s Customer Response Center at 1-888-725-0016. Hours are Monday through Friday from 8:30 AM to 5:30 PM Eastern Time.


We publish reports on this website which detail our  support to a variety of US and Puerto Rico based health-related nonprofit organizations that foster increased understanding of scientific, clinical, and healthcare issues, and contribute to improving patient care. This includes financial support through contributions, memberships, and sponsorships.

Examples include:

Funding to patient advocacy organizations: Among the nonprofits we support are patient groups that provide patients, their families, and friends with support and information on how to live with a disease.

Funding to Healthcare Professional Associations (HPAs) – We support medical, disease-oriented, or scientific policy organizations that have a significant percentage of members who are physicians, and that represent their interests by providing information and services, support for increased medical research, and/or access to healthcare but do not recommend medicines. This excludes medical education companies, hospitals, business organizations, government agencies, and for-profit companies. Examples include: American Medical Association, American Academy of Nurse Practitioners, and the American Academy of Pediatrics.

Funding to support third-party educational activities – In the US, we award a limited number of competitive grants to fund independent third-party educational activities for physicians that are clearly designed to close documented gaps in patient care. These activities are designed and implemented by third-party, nonprofit educational providers with no GSK control, influence or involvement. More information about our competitive process and funded grants is available on our website.

Community Partnership charitable grants are also provided based on community needs, independent from our therapeutic areas of interest. All requests are subject to the availability of funding. More information is available in the Our work with communities section of our company website.

GSK has strict, objective criteria in place to govern the grant funding and approval process. Requests are evaluated on the basis of alignment with our educational objectives and our therapeutic areas of interest.

Our policies prohibit offering funding in return for any prescribing, purchasing, or recommendations for our products. We also have processes in place and work diligently to help ensure that our support is in compliance with all applicable laws, rules and regulations, including the guidelines and standards set by the Office of Inspector General (OIG), the Accreditation Council for Continuing Medical Education (ACCME) and other national accrediting organizations, the American Medical Association, the US Food and Drug Administration (FDA), and the Pharmaceutical Research and Manufacturers of America Code.

Research Payments

We compensate research institutions for participating in studies that help evaluate the safety and efficacy of a medicine. These studies relate to all phases of medicine and product discovery and development, including nonclinical research studies and Phase I-IV clinical trials. Our payments cover the costs of treating a patient, and additional costs related to testing (blood work for example). 

The report covers research conducted for all R&D business units, consumer healthcare (over-the-counter medicines), Stiefel, and vaccines. The studies include GSK-sponsored or GSK-supported studies started after January 1, 2010, where the Principal Investigator or Lead Researcher is a US-licensed healthcare professional.

The report does not include individual travel and expense reimbursements to US healthcare professionals for study-related investigator meetings.

GSK has set a limit on payments to individual US physicians for speaking, advising, other transfers of value, and other expenses of $100,000 per calendar year.  This limit does not include payments for clinical trials made to healthcare or research institutions / organizations.

For more information regarding GSK’s approach to research and research disclosure, please see the Research Practices section of GSK’s Corporate Responsibility Report.